Literature DB >> 10518584

Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation.

L Lin1, B Georgievska, A Mattsson, O Isacson.   

Abstract

A number of in vitro studies have shown that activation of muscarinic receptors by cholinergic agonists stimulates the nonamyloidogenic, alpha-secretase-processing pathway of amyloid precursor protein (APP). To determine whether increased cholinergic neurotransmission can modify the APP processing in vivo, we administered a muscarinic receptor agonist (RS86) to normal or aged rats and rats with severe basal forebrain cholinergic deficits (induced by 192 IgG-saporin). The levels of the cell-associated APP in neocortex, hippocampus, and striatum, as well as the secreted form of APP (APPs) in cerebrospinal fluid, were examined by Western blots. Additionally, we investigated the association between the altered APP levels and behavioral deficits caused by cholinergic lesions. We found that treatment with muscarinic receptor agonist resulted in decreased APP levels in neocortex and hippocampus and increased levels of APPs in cerebrospinal fluid. Regulation of APP processing by the muscarinic agonist treatment occurred not only in normal rats, but also in aged and cholinergic denervated rats that model this aspect of Alzheimer's disease. Interestingly, we found that elevation of APP in neocortex correlated with the cognitive deficits in water-maze testing of rats with cholinergic dysfunction. These data indicate that increased cholinergic neurotransmission can enhance nonamyloidogenic APP processing in intact and lesioned rats and that APP may be involved in cognitive performance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10518584      PMCID: PMC18420          DOI: 10.1073/pnas.96.21.12108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C.

Authors:  A Caputi; S Barindelli; L Pastorino; M Cimino; J D Buxbaum; F Cattabeni; M Di Luca
Journal:  J Neurochem       Date:  1997-06       Impact factor: 5.372

2.  Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein.

Authors:  J Nalbantoglu; G Tirado-Santiago; A Lahsaïni; J Poirier; O Goncalves; G Verge; F Momoli; S A Welner; G Massicotte; J P Julien; M L Shapiro
Journal:  Nature       Date:  1997-05-29       Impact factor: 49.962

3.  Expression of amyloid precursor protein mRNA isoforms in rat brain is differentially regulated during postnatal maturation and by cholinergic activity.

Authors:  J Apelt; R Schliebs; M Beck; S Rossner; V Bigl
Journal:  Int J Dev Neurosci       Date:  1997-02       Impact factor: 2.457

4.  Memory impairment and neuronal dysfunction induced by beta-amyloid protein in rats.

Authors:  T Nabeshima; A Nitta
Journal:  Tohoku J Exp Med       Date:  1994-11       Impact factor: 1.848

Review 5.  From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease.

Authors:  R M Nitsch
Journal:  Neurodegeneration       Date:  1996-12

6.  Selective lesioning of the basal forebrain cholinergic system by intraventricular 192 IgG-saporin: behavioural, biochemical and stereological studies in the rat.

Authors:  G Leanza; O G Nilsson; R G Wiley; A Björklund
Journal:  Eur J Neurosci       Date:  1995-02-01       Impact factor: 3.386

7.  Tyrosine phosphorylation-dependent stimulation of amyloid precursor protein secretion by the m3 muscarinic acetylcholine receptor.

Authors:  B E Slack; J Breu; M A Petryniak; K Srivastava; R J Wurtman
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

8.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein.

Authors:  D Games; D Adams; R Alessandrini; R Barbour; P Berthelette; C Blackwell; T Carr; J Clemens; T Donaldson; F Gillespie
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

9.  Regional alteration of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome).

Authors:  J L Fiedler; C J Epstein; S I Rapoport; R Caviedes; P Caviedes
Journal:  Brain Res       Date:  1994-09-26       Impact factor: 3.252

10.  Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein.

Authors:  P M Moran; L S Higgins; B Cordell; P C Moser
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

View more
  18 in total

Review 1.  Neuroprotective strategies in Alzheimer's disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  NeuroRx       Date:  2004-01

2.  GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity.

Authors:  Shaowu Cheng; Longxuan Li; Shuangteng He; Jun Liu; Yuning Sun; Minchao He; Kenneth Grasing; Richard T Premont; William Z Suo
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

Review 3.  Beta-amyloid and cholinergic neurons.

Authors:  Vladimír Dolezal; Jana Kasparová
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

4.  D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease.

Authors:  Y Kashiwaya; T Takeshima; N Mori; K Nakashima; K Clarke; R L Veech
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 5.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

6.  Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.

Authors:  Rodrigo Medeiros; Masashi Kitazawa; Antonella Caccamo; David Baglietto-Vargas; Tatiana Estrada-Hernandez; David H Cribbs; Avraham Fisher; Frank M LaFerla
Journal:  Am J Pathol       Date:  2011-06-23       Impact factor: 4.307

Review 7.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

8.  Cystatin C prevents neuronal loss and behavioral deficits via the endosomal pathway in a mouse model of down syndrome.

Authors:  Gurjinder Kaur; Sebastien A Gauthier; Rocio Perez-Gonzalez; Monika Pawlik; Amol Bikram Singh; Benjamin Cosby; Panaiyur S Mohan; John F Smiley; Efrat Levy
Journal:  Neurobiol Dis       Date:  2018-09-01       Impact factor: 5.996

9.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.

Authors:  Pamela E Potter; Paula K Rauschkolb; Yoga Pandya; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2011-05-01       Impact factor: 17.088

10.  Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioral, and neurotoxic effects of methamphetamine.

Authors:  David Weinshenker; Michela Ferrucci; Carla L Busceti; Francesca Biagioni; Gloria Lazzeri; L Cameron Liles; Paola Lenzi; Livia Pasquali; Luigi Murri; Antonio Paparelli; Francesco Fornai
Journal:  J Neurochem       Date:  2007-11-26       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.